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Campylobacter jejuni is a zoonotic pathogen and the most common bacterial cause
of human gastroenteritis worldwide. With the increase of antibiotic resistance to
fluoroquinolones and macrolides, the drugs of choice for treatment, C. jejuni was
recently classified as a serious antimicrobial resistant threat. Here, we characterized
94 C. jejuni isolates collected from patients at four Michigan hospitals in 2011 and 2012
to determine the frequency of resistance and association with phylogenetic lineages.
The prevalence of resistance to fluoroquinolones (19.1%) and macrolides (2.1%) in
this subset of C. jejuni isolates from Michigan was similar to national reports. High
frequencies of fluoroquinolone-resistant C. jejuni isolates, however, were recovered from
patients with a history of foreign travel. A high proportion of these resistant isolates were
classified as multilocus sequence type (ST)-464, a fluoroquinolone-resistant lineage that
recently emerged in Europe. A significantly higher prevalence of tetracycline-resistant
C. jejuni was also found in Michigan and resistant isolates were more likely to represent
ST-982, which has been previously recovered from ruminants and the environment
in the U.S. Notably, patients with tetracycline-resistant C. jejuni infections were more
likely to have contact with cattle. These outcomes prompt the need to monitor the
dissemination and diversification of imported fluoroquinolone-resistant C. jejuni strains
and to investigate the molecular epidemiology of C. jejuni recovered from cattle and farm
environments to guide mitigation strategies.
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INTRODUCTION
Campylobacter spp. are Gram negative bacteria responsible for the greatest number of
cases of bacterial gastroenteritis worldwide (World Health Organization [WHO], 2013). It is
estimated that 1.3 million Campylobacter infections occur every year in the U.S., resulting in
13,000 hospitalizations and 120 deaths, with C. jejuni comprising almost 90% of the cases
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(Centers for Disease Control and Prevention [CDC], 2015).
Furthermore, previous studies have demonstrated an association
between campylobacteriosis and autoimmune diseases such as
Guillain Barré syndrome (Nachamkin et al., 1998), reactive
arthritis (Zia et al., 2003), and irritable bowel syndrome (Connor,
2005). Campylobacter spp. have a broad host range and can
colonize the intestinal tracts of chickens, turkeys, pigs and
ruminants without causing clinical signs (Altekruse et al., 1999;
Stanley and Jones, 2003). These pathogens can also survive in
water and soil for extended periods of time, up to several months
(Jones, 2001; Pitkänen, 2013). The consumption of contaminated
poultry is the primary source of sporadic human Campylobacter
infections (Kaakoush et al., 2015), while approximately 66%
of Campylobacter outbreaks are attributed to dairy products,
mostly raw milk or cheese (Interagency Food Safety Analytics
Collaboration Project, 2015). Direct transmission from animal
sources including household pets such as dogs and cats, has also
been reported (Damborg et al., 2004).
The most common clinical presentation of campylobacteriosis
is self-limiting gastroenteritis with vomiting, cramping, and
diarrhea lasting for 7–10 days in most cases (Peterson,
1994). Many individuals develop more severe and prolonged
infections. Extraintestinal spread of the bacterium, for example,
can lead to bacteremia and infection of other organs in
some individuals (Man, 2011). Infants, geriatric patients, and
immunocompromised individuals more commonly require
treatment with antibiotics to combat C. jejuni infections
(Guerrant et al., 2001). Ciprofloxacin, a fluoroquinolone that
inhibits DNA synthesis by targeting gyrA and macrolides such as
azithromycin and erythromycin, which hinder bacterial protein
biosynthesis by targeting 23S rRNA, have been recommended as
the first line antimicrobials. Yet, resistance to both antimicrobials
has emerged and increases in resistance frequencies have
been reported (Zhou et al., 2015). Indeed, the proportion
of Campylobacter isolates resistant to fluoroquinolones has
increased from 14.2% in 1998 to 25.3% in 2012 in the U.S.
(Centers for Disease Control and Prevention [CDC], 2014).
Campylobacter resistance to fluoroquinolones and macrolides
is conferred by point mutations in their target sites, the gyrA
and 23S rRNA genes, respectively (Payot et al., 2006). The
C257T point mutation in gyrA that yields a Thr-86-Ile amino
acid change is the most frequently observed mutation that leads
to high-level resistance to quinolone, i.e., nalidixic acid, and
fluoroquinolone (Iovine, 2013). For macrolides, point mutations
of A2074C, A2074G, and A2075G in domain V of the 23S
rRNA gene, have been found to confer a high-level of resistance
[Minimal inhibitory concentration (MIC) >128 µg/mL], while
A2074T has been shown to confer a low-level of resistance
(MIC = 8 µg/mL) (Vacher et al., 2005). The presence of the 23s
rRNA methyltransferase gene ermB and an amino acid change in
L4/L22 ribosomal proteins also have been described as resistance
mechanisms for macrolides (Pérez-Boto et al., 2010; Wang et al.,
2014). In addition, the active eﬄux pump, CmeABC, works
synergistically with point mutations in these gene targets to
simultaneously resist the action of fluoroquinolone, macrolide,
tetracycline, beta-lactam, and ketolide antimicrobials (Zhang,
2008).
Tetracycline has been suggested as an alternative treatment
for patients with systemic Campylobacter infections (Guerrant
et al., 2001), but it is rarely used in practice. On the other
hand, tetracycline is widely used in food animals like chickens
and cattle for preventive and growth promoting purposes and
treatment, e.g., in sheep for abortion (Giguere et al., 2006).
In Campylobacter, resistance to tetracycline is conferred by
tet(O), which has been found widely in isolates recovered from
various sources (Connell et al., 2003). tet(O) encodes a ribosomal
protection protein that induces a conformational change upon
binding to the bacterial ribosome, the target site for tetracycline.
This binding results in the release of the bound tetracycline
molecule. A prior study has identified the tet(O) gene in plasmids
in the majority of isolates from campylobacteriosis cases (Gibreel
et al., 2004), though it has also been identified in the bacterial
chromosome (Wu et al., 2014).
In the U.S., the FoodNet surveillance system was designed
to monitor the incidence of common foodborne pathogens,
including Campylobacter, while the National Antimicrobial
Resistance Monitoring System (NARMS) was implemented to
examine antimicrobial resistance trends. Michigan is not one
of the 10 states included in the FoodNet system, however,
Campylobacter was the most common foodborne pathogen
reported through the Michigan Disease Surveillance System
(MDSS) in the past decade (2004–2013). As a result, this study
was undertaken to determine the frequency of antimicrobial
resistance in a subset of C. jejuni isolates collected in Michigan
between 2011 and 2012, and to estimate the genetic diversity
of both susceptible and resistant isolates using multilocus
sequence typing (MLST). We hypothesized that the frequency
of antimicrobial resistance in C. jejuni isolates recovered from
Michigan patients is similar to national frequencies, but that
specific risk factors, which may be unique to this patient
population, are associated with resistant infections. Identifying
which lineages are associated with resistance and estimating
their frequency in different populations is important for disease
prevention efforts aimed at controlling resistance emergence and
more rapidly detecting resistant infections.
MATERIALS AND METHODS
Study Population and Campylobacter
Isolation
From 2011 to 2012, we obtained C. jejuni isolates from
patients with campylobacteriosis identified via the Michigan
State University (MSU) Enteric Research Investigative Network
(ERIN) surveillance system. This system was established in
collaboration with the Michigan Department of Health and
Human Services (MDHHS) and four major hospitals in
Michigan. All protocols were approved by the Institutional
Review Boards at Michigan State University (IRB# 10-736SM),
the MDHHS (842-PHALAB), and each participating hospital.
Isolates were cultured on tryptone soy agar plates with sheep
blood and cefoperazone (20 µg/mL), amphotericin B (4 µg/mL),
and vancomycin (20 µg/mL) using microaerophilic conditions at
37◦C for 48 h. Multiplex PCR was performed on the extracted
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DNA to confirm the species following previously described
protocol (Yamazaki-Matsune et al., 2007). The isolates were
stored in tryptone soy broth with 10% glycerol at −80◦C until
further testing.
Epidemiological Data
Demographic and epidemiological data were retrieved from
the MDSS1 and managed using Microsoft Access and Excel.
Three cases were not Michigan residents, but developed
campylobacteriosis while traveling in Michigan and thus,
epidemiological data was transferred to the respective states.
The C. jejuni isolates from these cases were included in the
overall genetic diversity and resistance prevalence estimates, but
were excluded from further analyses. A patient was considered
to have a history of travel only when the traveling period was
within 1 week prior to the onset of symptoms. For animal
contact, birds were defined as poultry, including chickens, ducks,
and turkeys, while ruminants were defined as cattle, sheep and
goats, and domestic animals were defined as household pets
such as dogs and cats. The season was classified based on the
onset date of symptoms: spring (March, April, May), summer
(June, July, August), fall (September, October, November), and
winter (December, January, February). Food history represents
consumption of specific foods (e.g., frozen chicken, home-
prepared chicken, etc.) within a week prior to onset of symptoms.
Phenotypic Antimicrobial Susceptibility
Profiling
The MICs of nine antimicrobials were determined by a
standard broth microdilution test following the guidelines of
the Clinical and Laboratory Standards Institute [CLSI] (2015).
The Sensititre system (Trek Diagnostic Systems, Thermo Fisher
Scientific Inc., Cleveland, OH, USA) was used for each isolate
following the manufacturer’s instructions. Antimicrobials
included ciprofloxacin (fluoroquinolone), nalidixic acid
(quinolone), azithromycin (macrolide), erythromycin
(macrolide), tetracycline, florfenicol, telithromycin, clindamycin,
gentamicin, and C. jejuni ATCC 33560 was used as the
quality control strain for every batch. The breakpoints for
each antimicrobial were determined using epidemiologic cut-
off values (ECOFFs), following the guidelines of European
Committee on Antimicrobial Susceptibility Testing [EUCAST]
(2015), per current protocol of the NARMS (Centers for Disease
Control and Prevention [CDC], 2014). If bacterial growth
was observed at the highest MIC tested (e.g., 64 µg/mL for
tetracycline), then the MIC for the isolate was interpreted as
greater than the highest MIC, i.e., > 64 µg/mL.
Whole Genome Sequencing
DNA was extracted from all 94 C. jejuni isolates using the
Wizard genomic DNA purification kit (Promega, Madison,
WI, USA) and the concentrations were measured using a
Qubit fluorometer (Life Technologies; Invitrogen, Carlsbad,
CA, USA). A total of 1ng of DNA per isolate was used
1http://www.michigan.gov/mdhhs/0,5885,7-339-71550510431274---,00.html
for library preparation with the Nextera XT kit (Illumina,
San Diego, CA, USA) following manufacturer’s instruction.
Validation of the library size and quantity was performed using
Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) and
KAPA library quantification kit (Kapa Biosystems, Woburn,
MA, USA), respectively. The libraries were pooled together for
denaturing and sequencing on a MiSeq (Illumina) platform for
2 × 250 reads at the Research Technology Support Facility
at MSU. Genomic assemblies were performed de novo using
Velvet, 1.2.07 (Zerbino and Birney, 2008) after trimming with
Trimmomatic (Bolger et al., 2014), followed by quality checking
with FastQC2. Assemblies were constructed using different
kmer values (31, 33, and 35), and the assembly yielding the
best N50 value for each isolate was used for downstream
analyses.
Multilocus Sequence Typing
The MLST profile of each sample was initially determined
using the web-based server3 with both the assembled contigs
and extracted alleles from whole genome sequences. Each
gene sequence was also confirmed by PCR-based MLST, as
described previously (Dingle et al., 2001). Allele, sequence
type (ST), and clonal complex (CC) assignments were made
using the PubMLST database4 (Jolley and Maiden, 2010).
New alleles (n = 4) and STs (n = 6) identified in this
study were deposited in the PubMLST database (id 24892-
28175).
In Silico Analysis of Resistance Genes
Sequences specific for gyrA and 23S rRNA were extracted from
the draft genomes based on reference sequences available via the
National Center for Biotechnology Information using the Basic
Local Alignment Search Tool (BLAST) (Altschul et al., 1990)
(gyrA: GenBank KU693342-KU693435; 23S rRNA: GenBank
KU891692-KU891785). Regions of the 23S rRNA and gyrA genes,
which include the typical point mutation sites associated with
resistance to macrolides and fluoroquinolones, respectively, were
aligned by MegAlign (DNAstar, Madison, WI, USA). Sanger
sequencing was used to confirm the point mutations identified
in 47 strains relative to the ATCC 33560 C. jejuni strain (gyrA:
GenBank KU693436; 23S rRNA KU891786), as described in prior
studies (Vacher et al., 2003; Said et al., 2010). The presence of
tet(O) was determined from the genome sequences and further
confirmed by PCR using a published protocol (Gibreel et al.,
2004).
Data Analysis
The frequency map of all campylobacteriosis cases reported in
Michigan between 2011 and 2012 (n = 1,449) was generated
using ArcMap GIS software (version 10.2; ESRI, Redlands, CA,
USA) using the data extracted from MDSS.
To identify evolutionary relationships between C. jejuni
isolates, a Neighbor-joining phylogeny (p-distance) with 1,000
2http://www.bioinformatics.babraham.ac.uk/projects/fastqc/
3www.cbs.dtu.dk/services/MLST
4http://pubmlst.org/campylobacter/
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bootstrap replications was constructed in MEGA6 (Tamura et al.,
2013) based on seven MLST loci. Clusters or CCs were classified
as STs that grouped together with >70% bootstrap support,
and parsimonious informative sites were further evaluated for
evidence of genetic recombination using Splitstree4 (Huson and
Bryant, 2006).
Statistical analyses were performed using SAS version 9.3
(SAS Institute, Cary, NC, USA). Differences in the frequencies
of antimicrobial resistance across ST, CC, and other variables
including disease presentation, were examined using χ2 and
Fisher’s exact tests for dichotomous variables, and the student’s
t-test for continuous variables; p < 0.05 was considered
significant. Multivariate analyses were performed using logistic
regression with any independent variables that yielded a p-value
of less than 0.2 or were plausibly linked to resistant C. jejuni
infections, e.g., age, sex. The model was built using a forward
stepwise method with the requirement for a significance level of
≤0.1 to remain in the model.
RESULTS
Description of Campylobacter Cases
Identified in Michigan
Ninety four C. jejuni isolates were recovered from clinical cases of
campylobacteriosis identified at four hospitals between January
2011 and December 2012. Among the 94 cases, more than 50%
(n = 52) were male, while 39 cases were female patients; the sex
was not known for three cases. Children 2 years and younger
(22.3%; n = 21) and adults older than 50 years (25.5%; n = 24)
comprised about half of the total cases. Race was available for 80
of the 94 cases, and the majority identified as Caucasian (n = 60;
75.0%).
A total of 1,449 laboratory confirmed Campylobacter cases
were reported in Michigan in 2011 and 2012 and the frequency
of reported cases varied across counties (Figure 1). The
participating hospitals and most of the residences of the cases
included in this study were in counties with higher population
densities and a greater frequency of campylobacteriosis.
Particularly, cases residing in Wayne, Washtenaw and Oakland
counties, which represent the counties with the highest
disease frequency, comprised 66.7% (n = 58) of the total
cases.
Sixty-eight cases had travel history information, among which
nine (13.2%) had a history of foreign travel, while 13 (19.1%)
had a history of domestic travel in the week prior to the onset of
symptoms (Table 1). Four cases had a history of domestic travel
outside Michigan, while three cases from other states (Ohio, New
Jersey, and Georgia) developed symptoms and were diagnosed
with campylobacteriosis while traveling in Michigan. Among the
64 cases with a history of animal contact, 38 (59.4%) had contact
with domestic animals including dogs and cats. Contact with
ruminants, which were all identified as cattle, was reported in
seven cases (10.9%), while six cases (9.4%) reported contact with
birds such as chickens and ducks. Six of the cases reporting
contact with cattle (85.7%) and five of the cases with bird contact
(83.3%) also reported contact with dogs and cats.
Antimicrobial Resistance Profiles of
C. jejuni Isolates and Mechanisms of
Resistance
Thirty isolates (31.9%) were susceptible to all nine antimicrobial
agents tested, while 64 isolates (68.1%) were resistant to one or
more agents. The highest frequency of resistance was observed
for tetracycline (n = 58 isolates; 61.7%), followed by resistance
to both ciprofloxacin and nalidixic acid (n = 18 isolates; 19.1%)
(Table 2). All C. jejuni isolates resistant to ciprofloxacin and
nalidixic acid showed high MICs (4–32 µg/mL, ≥64 µg/mL,
respectively). Resistance to florfenicol was detected in one isolate
(1.1%), and all isolates were susceptible to gentamicin. A total
of 15 isolates (16.0%) were resistant to two or more classes of
antibiotics. Thirteen (13.8%) of these isolates were resistant to
ciprofloxacin, nalidixic acid, and tetracycline, while two isolates
(2.1%) were resistant to both azithromycin and erythromycin
as well as ciprofloxacin, nalidixic acid, telithromycin, and
clindamycin.
All 18 C. jejuni isolates that were phenotypically resistant to
ciprofloxacin had a point mutation at 257 in gyrA; 17 isolates
had the C257T mutation resulting in an amino acid change of
Thr-86-Ile, while one isolate had double mutations (C257G and
A258G) resulting in a Thr-86-Arg change. Two isolates that were
resistant to azithromycin and erythromycin had an A2074T point
mutation in 23S rRNA, and all 58 tetracycline resistant isolates
harbored tet(O).
Epidemiological Associations with
Antimicrobial Resistant C. jejuni
Infections
To identify factors associated with antimicrobial resistant
C. jejuni infections, we conducted univariate analyses using
demographic and epidemiological data (Supplementary Table
S1). Notably, cases reporting a history of foreign travel had a
higher likelihood of fluoroquinolone-resistant C. jejuni infections
(Fisher’s p < 0.0001) with an odds ratio (OR) of 35.7 (exact 95%
CI; 4.6, 395.3). In detail, among the nine cases with foreign travel
history, seven were resistant to ciprofloxacin and nalidixic acid;
six of these isolates were also resistant to tetracycline, yielding a
significant association between foreign travel and the following
resistance profile: ciprofloxacin-, nalidixic acid-, tetracycline-
resistance (CipNalTet) (Fisher’s p < 0.0001; OR = 35.3). Cases
with CipNalTet infections were significantly more common
during the winter months of December, January, and February
(Fisher’s p < 0.05; OR = 5.7), while eating chicken prepared at
home was protective for both CipNalTet infections (p < 0.01;
OR = 0.0) and fluroquinolone-resistant infections (p < 0.01;
OR = 0.08). By contrast, contact with cattle was associated with
tetracycline-resistant infections (Fisher’s p < 0.05; OR= infinity)
and cases reporting consumption of frozen chicken were
less likely to have tetracycline-resistant infections (p < 0.05;
OR= 0.2).
Multivariate analysis was conducted to identify predictors
of fluoroquinolone-resistant infections in all 94 cases using the
factors with significant associations (p < 0.2) identified in the
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FIGURE 1 | GIS map of Michigan by county showing the frequency of Campylobacter cases reported in 2011–2012. The stars represent the location of
four hospitals where the samples were collected.
univariate analyses as well as biologically plausible factors such
as age, sex (Table 3). History of foreign travel was associated
with fluoroquinolone-resistant infections regardless of age and
sex; the OR was 33.4 (95% CI = 3.9–285.2) in the final
model. When the same multivariate analysis was performed
for CipNalTet infections, history of foreign travel (OR = 54.2;
95% CI = 4.1–717.1) and winter (OR = 25.3; 95% CI = 1.6–
405.7) were independently associated with infection. However,
there was no association between foreign travel history and
season, including winter. Although having chicken prepared at
home was a protective factor in the univariate analysis, this
variable could not be examined in the multivariate models as it
significantly reduced the sample size due to missing data in 37 of
the cases.
Genetic Diversity and Phylogenetic
Structure of C. jejuni
A total of 49 different STs, including six novel STs, were
represented among the 94 C. jejuni isolates recovered in Michigan
(Figure 2). These STs were assigned to 17 CCs, while 11 STs were
singletons. The six new STs were assigned to ST-6749 (CC-353),
ST- 6751 (CC-61), ST-6752 (CC-353), ST-6788 (CC-1332), ST-
7009 (CC unassigned), and ST-7010 (CC unassigned). The most
prevalent STs were ST-982 (n = 10; 10.6%) and ST-353 (n = 9;
9.6%), followed by ST-45 (n = 7; 7.4%), ST-50 (n = 5; 5.3%) and
ST-48 (n = 4; 4.3%). Thirty four of the remaining STs had only
one isolate assigned to each ST.
The MLST-based Neighbor-joining phylogeny for all 94
isolates showed that some STs were closely related, though the
bootstrap values were low, which is likely due to the high
diversity and frequent recombination among STs in this isolate
population. Indeed, an evaluation of the 144 parsimonious
informative sites provided evidence of significant recombination
[pairwise homoplasy index (PHI) = 0.0] among the STs via
a Neighbor-net analysis (Supplementary Figure S1). In order
to elucidate the ST distribution and evolutionary relationships
of isolates that were restrictively derived from Michigan, we
excluded cases with foreign travel and history of travel outside
of Michigan as well as cases with missing data. A total of
36 different STs, including four novel STs, represented the 52
Michigan cases without any history of travel (n = 46) or travel
only within Michigan (n = 6). Although there was still evidence
of recombination between these isolates, the phylogenetic tree
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showed enhanced bootstrap support, and six distinct clusters
with bootstrap support values exceeding 70% were identified
(Figure 3, Supplementary Figure S2).
Association between Phylogenetic
Lineage, Epidemiologic Data, and
Resistance
Multiple epidemiological factors were associated with specific
C. jejuni genotypes. For example, individuals reporting a
history of foreign travel were more likely to have infections
caused by ST-464 (CC-464) isolates (Fisher’s p < 0.05),
while infection with ST-982 was associated with cattle contact
(Fisher’s p < 0.05). Drinking water obtained from a well
at home (Fisher’s p < 0.05), and contact with birds, i.e.,
chickens (Fisher’s p < 0.01) were also associated with ST-
982 infections, while contact with birds, i.e., chickens (Fisher’s
p < 0.05) and female gender (χ2 p < 0.05) were both
associated with CC-21 (n = 25) infections. In addition, cases
older than 50 years of age were more likely to have isolates
TABLE 1 | Description of cases included in the study.
Demographic data No. of cases† (%)‡ Epidemiologic data No. of cases† (%)‡
Sex Travel
Male 52 57.1% No travel 46 67.6%
Female 39 42.9% Domestic travel 13 19.1%
Age group (years) Foreign travel 9 13.2%
≤2 21 22.3% Animal contact
3–23 25 26.6% Reptile 0 0%
24–50 24 25.5% Livestock 7 10.9%
>50 24 25.5% Birds/poultry 6 9.4%
Race Domestic 38 59.4%
Caucasian 60 75.0% Others 5 7.8%
African American 9 11.3% Food consumption
Asian 1 1.2% Ground meats 33 55.0%
Others 10 12.5% Home prepared chickens 30 50.0%
Residence (county) Frozen chickens 14 23.3%
Clinton 4 4.6% Restaurant chickens 19 31.7%
Ingham 8 9.2% Raw sprouts 4 6.7%
Livingston 6 6.9% Raw milk 4 6.7%
Macomb 3 3.4% Water at home
Oakland 10 11.5% Well 12 19.0%
Washtenaw 17 19.5% Municipal 42 66.7%
Wayne 31 35.6% Bottled 7 11.1%
Others 8 9.2% Others 2 3.2%
† Counts for sex, age group, race, travel history, and water source at home are mutually exclusive for each category; counts for animal contact and food consumption are
repeated across categories as they are reported. ‡The percentages are based on the number of cases for which information was available. Total number of cases varies
between variables due to the difference in missing information.
TABLE 2 | Frequency (%) of antimicrobial resistance and minimum inhibitory concentration (MIC) of human C. jejuni isolates in Michigan.
CLSI
Antimicrobial class
Antimicrobial agent % Resistance
(n = 94)
MIC (µg/mL)
Range MIC50 MIC 90
Fluoroquinolone Ciprofloxacin 19.15% (18) <0.015 ∼ 32 0.12 8
Quinolone Nalidixic acid 19.15% (18) <4 ∼ > 64 4 >64
Macrolide Azithromycin 2.13% (2) <0.015 ∼ > 64 0.06 0.12
Erythromycin 2.13% (2) < 0.03 ∼>64 0.5 1
Aminoglycoside Gentamicin 0 < 0.12 ∼ 1 0.5 1
Tetracycline Tetracycline 61.7% (58) < 0.06 ∼ > 64 64 >64
Lincosamide Clindamycin 2.13% (2) < 0.03 ∼ > 16 0.12 0.25
Ketolide Telithromycin 2.13% (2) <0.015 ∼ > 8 1 2
Phenicol Florfenicol 1.06% (1) < 0.03 ∼ 32 1 2
† CLSI: Clinical and Laboratory Standards Institute.
Frontiers in Microbiology | www.frontiersin.org 6 April 2016 | Volume 7 | Article 589
fmicb-07-00589 April 22, 2016 Time: 11:38 # 7
Cha et al. Antimicrobial Resistance and Genetic Diversity of C. jejuni
TABLE 3 | Univariate and multivariate analyses of factors associated with fluoroquinolone resistant C. jejuni infections among all cases (n = 94).
Characteristic Univariate analysis Multivariate analysis
OR 95% CI† p OR 95% CI† p
Foreign travel 35.7 5.78–220.38 <0.0001 33.4 3.9–285.2 0.0013
Season (Winter) 3.27 0.92–11.58 0.056 8.1 0.9–72.7 0.0614
Age (years)∗ – – – 1.05 0.99–1.1 0.0536
Sex (Female) 0.92 0.32–2.68 0.88 – – –
Domestic animal contact 0.37 0.10–1.33 0.19 0.26 0.041–1.659 0.1542
Home prepared chicken∗∗ 0.082 0.0095–0.71 0.0095 – – –
∗Age (years) is a continuous variable; not proper for univariate analysis used (χ2 or Fisher’s exact test). ∗∗Consumption of home prepared chicken was a significant
protective factor by univariate analysis; however, it was not used for multivariate analysis because of the small sample size left when the characteristic was included in the
base model. †Wald Confidence interval
belonging to CC-45 (n = 9) relative to all other CCs (Fisher’s
p < 0.05).
Among the 52 cases without any history of travel or travel only
within Michigan, similar associations were observed. Notably,
contact with birds, i.e., chickens, was associated with both ST-
982 (Fisher’s p < 0.01) and CC-21 (Fisher’s p < 0.05) infections.
Because the phylogenetic clusters were better defined in the
isolate population recovered exclusively from Michigan cases
(Figure 3), we also analyzed epidemiologic associations by
clusters identified in the Neighbor joining phylogeny (Figure 3).
Isolates belonging to Cluster V, which includes ST-982 and
the 4 other STs, all representing CC-21, were significantly
associated with contact with birds, i.e., chickens (Fisher’s
p < 0.05). Additionally, when compared to other clusters,
the two cases reporting contact with cattle were included
in Cluster V; however, the association was not significant
(Fisher’s p = 0.0571), which may be due to the small sample
size.
It is also notable that the three isolates assigned to ST-464
had the same profile with resistance to ciprofloxacin, nalidixic
acid and tetracycline (CipNalTet). A significant association was
observed between ST-464 and resistance to ciprofloxacin and
nalidixic acid (Fisher’s p < 0.01), as well as CipNalTet (Fisher’s
p < 0.01). Similarly, the isolates belonging to ST-982 had a higher
likelihood of having resistance to tetracycline when compared
to all other lineages (Fisher’s p < 0.05). No other significant
associations were observed for other STs or CCs with specific
resistance profiles.
DISCUSSION
Increasing frequencies of resistance to antimicrobials in C. jejuni
is a growing public health concern worldwide. In the U.S.,
NARMS monitors resistance trends by testing C. jejuni isolates
collected from 10 states across the country; however, Michigan
is not included in this system. Hence, this represents the
first study reporting the antimicrobial resistance profiles and
genetic diversity of C. jejuni recovered from patients in
Michigan collected via active surveillance. The high frequency
of resistance to several important antimicrobials including the
fluoroquinolones and macrolides, which are commonly used to
treat human infections, is of concern as are the risk factors for
resistant infections. Indeed, we found that a history of foreign
travel is the most important risk factor for fluoroquinolone-
resistant C. jejuni infections in Michigan, which is consistent
with prior reports in other geographic locations in the U.S.
(Smith et al., 1999; Kassenborg et al., 2004) and Europe (Engberg
et al., 2001; Rautelin et al., 2003; Norström et al., 2006).
A case-control study conducted using FoodNet surveillance
sites in the U.S. during 1998–1999, for instance, demonstrated
that history of foreign travel resulted in a higher likelihood
of acquiring fluoroquinolone-resistant Campylobacter infections
(OR = 7.6; 95% CI = 4.3-13.4) (Kassenborg et al., 2004). This
same study also found that consumption of poultry prepared
outside of the home was a risk factor for domestically acquired
fluoroquinolone-resistant infections (OR = 10.0, 95% CI = 1.3–
78). The latter result is similar to our finding that chicken
prepared at home was protective and resulted in a decreased
likelihood of having a fluoroquinolone-resistant infection. These
data are important as they demonstrate that the major sources
of fluoroquinolone-resistant C. jejuni infections are similar in
different parts of the U.S. even though disease frequencies
may vary. They also emphasize the importance of monitoring
patients with foreign travel history and considering individual
treatment schemes in order to more readily combat resistant
infections.
Prior studies have suggested that a high frequency of travel-
associated fluoroquinolone-resistant Campylobacter infections
may be due to a high prevalence of fluoroquinolone resistance in
the destination areas (Piddock, 1995; Smith et al., 1999). Recently,
clonal spread of specific fluoroquinolone-resistant lineages, e.g.,
ST-464, have been reported in Europe (Cody et al., 2012; Kittl
et al., 2013). According to the PubMLST database (Jolley and
Maiden, 2010), ST-464 has been frequently reported in Europe
and Asia, however, no prior reports have been noted in the U.S.
All three isolates assigned to ST-464 had the same resistance
profile (CipNalTet) and two of these isolates were from cases
that had traveled to Cambodia and to Italy, Turkey, Greece, and
France; travel status was missing for the remaining case. These
data suggest the dissemination of a fluoroquinolone-resistant ST-
464 lineage outside of Europe, warranting the need to enhance
surveillance efforts and identify factors associated with global
spread.
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FIGURE 2 | Neighbor-joining phylogeny of sequence types (STs) by antimicrobial resistance patterns, clonal complexes (CCs), and type of gyrA
mutation. The numbers at the end of each branch represent the STs found in this study, while the numbers at the nodes represent the bootstrap value from 1,000
replications. Non-synonymous mutation is noted by NS in parentheses; S in parentheses indicates synonymous mutation. Superscript FT indicates isolates
recovered from a case with foreign travel history. gyrA mutations were determined using C. jejuni ATCC 33560 as the reference; location 243, 357, 360 were defined
as CT variable regions. ∗6 of 9 isolates had a synonymous point mutation at C330T. ∗∗1 of 3 isolates had a synonymous point mutation at C330T.
From a total of 94 isolates, thirty six (38.3%) had at least
one point mutation in gyrA compared to the ATCC 33560
reference strain that is susceptible to all antimicrobials tested
(McDermott et al., 2004). Eighteen isolates had non-synonymous
point mutations conferring resistance to fluoroquinolones; the
amino acid changes, Thr-86-Ile and Thr-86-Arg, were observed
in 17 isolates and 1 isolate, respectively. Although the Thr-86-Arg
mutation was described as one of the mutations inducing high
MIC values for fluoroquinolones in Campylobacter spp. (Rossi
et al., 2015), this mutation is rarely reported. It is also notable that
only this isolate with Thr-86-Arg had transversion mutations,
C257G and A228C in gyrA (Figure 2). Interestingly, among the
17 isolates with a Thr-86-Ile mutation, 13 different STs were
represented and five of these were recovered from patients with a
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FIGURE 3 | Neighbor-joining phylogeny of sequence types (STs) from Michigan (n = 52). The numbers at the end of each branch represent the STs and
numbers at the nodes are bootstrap values following 1,000 replications.
history of foreign travel to multiple geographic locations. These
data demonstrate that fluoroquinolone resistance can develop
via similar point mutations in gyrA among phylogenetically
distinct Campylobacter lineages. No other pattern or association
was observed in the type or frequency of synonymous point
mutations in gyrA and specific resistance profiles or increased
MICs. However, notable associations were observed between STs
and the types of point mutations. For example, all seven isolates
assigned to ST-45 had a T234C point mutation, while the two
closely related lineages, ST-2875 and ST-7009, ST-468 and ST-
4185, respectively, contained identical synonymous gyrA point
mutations (Figure 2). Indeed, prior studies have suggested the
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use of gyrA as a genetic marker to investigate the relatedness of
C. jejuni strains (Ragimbeau et al., 2014). It is also important
to note that not all mutations were restricted to closely related
lineages. The C330T synonymous mutation in gyrA, for instance,
was found in ST-353, ST-6, ST-2310, and ST-21, distinct lineages
located in different branches of the phylogenetic tree.
Prior studies have detected variation in the level of resistance
to macrolides based on the type of mutation in 23S rRNA as
well. The A2074T mutation in 23S rRNA, for example, has
been linked to low macrolide resistance levels previously (Vacher
et al., 2005), while a recent study detected a high resistance
level (MIC > 512 µg/ml) in a C. jejuni strain from a human
clinical case (Ohno et al., 2016). Similar to the latter finding,
the two macrolide resistant isolates recovered from Michigan
had the same A2074T 23S rRNA mutation with high resistance
levels to both erythromycin and azithromycin (MIC> 64µg/ml).
Notably, these isolates were multiple drug resistant (MDR) with
resistance to four classes of antimicrobials including macrolides,
a fluoroquinolone, a lincosamide (clindamycin) and a ketolide
(telithromycin), suggesting that other resistance mechanisms
could impact the overall level of resistance. One example is the
cmeABC eﬄux pump, which has been linked to resistance to
multiple antimicrobials, including fluoroquinolones, macrolides,
and tetracycline. Both of the Michigan strains, however, were
susceptible to tetracycline. It is important to note that these
isolates, representing ST-5221 and ST-6, respectively, clustered
together in the Neighbor-joining phylogeny with ST-7010
(Figure 2), all of which contained a high frequency of similar
synonymous point mutations in 23S rRNA (Supplementary
Table S2). This finding suggests that some C. jejuni lineages
may be more susceptible to point mutations, which may lead
to antimicrobial resistance. Further studies are required to
determine whether specific synonymous mutations impact the
mutability of some isolates resulting in greater mutation rates or
enhanced fitness in vivo.
A significantly higher tetracycline resistance rate (61.7%) was
observed in the study samples when compared to the 2012
NARMS report (47.8%) (χ2 p < 0.01). All of the tetracycline-
resistant C. jejuni isolates (n = 58) harbored tet(O), which was
confirmed by both PCR and in silico analysis. Although we
could not determine whether tet(O) was plasmid-derived in all
of the isolates examined, the gene was found in multiple lineages
throughout the phylogeny, suggesting that plasmid-mediated
resistance and horizontal gene transfer across lineages is likely.
In addition, a significant association was observed between
ST-982 and tetracycline resistance as well as cattle contact.
According to the PubMLST database, ST-982 has previously been
reported from cattle (n = 14), cow’s milk (n = 4), the farm
environment (n = 3) and a lamb (n = 1) in the U.S., while
it was linked to human clinical cases in Canada and the U.K.
Another study conducted in the state of Washington (Davis et al.,
2013), however, recovered ST-982 isolates from both humans
and cattle. Taken together, these data suggest that this resistant
genotype has the ability to cross species and may be more likely
to acquire resistance to tetracycline. A significant association
was also observed between ST-982 and contact with chickens
and drinking well water at home, suggesting that this lineage
may be readily adaptable to different hosts and environments.
Further investigation of the genetic diversity and antimicrobial
resistance profiles of C. jejuni recovered from reservoir hosts
and the environment, however, is needed to better understand
transmission dynamics and host specificity.
Recent studies in Europe show mounting evidence that clonal
spread of specific fluoroquinolone-resistant C. jejuni lineages
may be contributing to the increasing trend of fluoroquinolone
resistance observed worldwide (Cody et al., 2012; Wimalarathna
et al., 2013; Kovacˇ et al., 2014). Our study affirms foreign
travel as a major risk factor for fluoroquinolone-resistant
infections in the U.S., and further suggests that specific resistant
lineages, like ST-464, may be emerging in the country. With
continuing globalization through imported food and foreign
travel, unified diagnostic guidelines on resistance detection and
global surveillance is warranted to track the emergence and
spread of these resistant lineages so effective mitigation strategies
can be implemented.
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